Probiotics

What are Probiotics?

According to the WHO, probiotics are live microorganisms which, when administered in adequate amounts, confer a health benefit on the host.

Despite the long history of probiotics being used to improve human health, we are currently witnessing a major resurgence of interest in the link between probiotics and the human microbiome. This renewed interest can be attributed to research advances in recent years, demonstrating the promising role that probiotics play in the prevention of certain infections and in reducing their intensity and duration.

Biotical Health, through its Probactis® product line, is committed to developing innovative and targeted probiotics for a healthy, balanced microbiota.

What sets us apart?

Active probiotic strains: Biotical is a pioneer in the development of active probiotic strains (APS), wich are genetically selected to effectively colonise the microbiota of the host through microbial antagonism (production of specific bactericides and metabolites).

Scientific evidence: probiotics are developed and manufactured with medicinal-grade precision and quality offering health professionals a safe probiotic backed by the leading clinical evidence in its field.

innovation: Our Probactis® product line includes a selection of targeted APS for specific pathologies.

Products

Probactis Strep®

Probactis Strep®is a food supplement based on Vitamin D and Streptococcus salivarius K12, a patented oral probiotic strain that protects from ear and throat infections.

Gluten free

Egg free

No refrigeration required

1 pill per day for 3 months before going to bed and after brushing teeth

Strawberry flavour

Tooth friendly

Probactis Strep® Kids

Probactis Strep®is a food supplement based on Vitamin D and Streptococcus salivarius K12, a patented oral probiotic strain that protects from ear and throat infections.

Gluten free

Egg free

No refrigration required

1 sachet per day for 3 months before going to bed and after brushing teeth

Strawberry flavour

Benefits

Reduces the frequency, duration, and severity of upper respiratory tract infections.1-4

Reduces the incidence of acute otitis media and improves the symptoms of secretory otitis media. 5

Reduces the use of antibiotics, antipyretics, and anti-inflammatories. 6

Unique sachet format for young children and lozenges format for children aged older than 5 years and adults.

Reduces the number of days missed from day care, school, or work. 3

Benefits

Reduces the frequency, duration, and severity of upper respiratory tract infections.1-4

Reduces the use of antibiotics, antipyretics, and anti-inflammatories 6

Unique sachet format for young children and lozenges format for children aged older than 5 years and adults.

Reduces the incidence of acute otitis media and improves the symptoms of secretory otitis media. 5

Reduces the number of days missed from day care, school, or work. 3

Endorsed with 40 scientific publications and 10 clinical studies published with Streptococus salivarius K12 (8 conducted with children)

=
Reduces the incidence of tonsillitis and pharyngitis by 86% 7
=

Reduces antibiotic use by 61.6% and anti-inflammatory use by 22.8% 6

=

Reduces the number of sick days by 53.7% 6

=

Reduces pharyngitis by 69% and otitis media by 48% in children 5

=

72% of adenoamigdelectomies cancelled 6

s

Warnings:

  • Store in a cool, dry place, preferably below 25ºC, away from light, heat, and moisture.
  • Keep out of reach of children.
  • Do not exceed the maximum recommended daily dose.
  • Food supplements are not a substitute for a varied and balanced diet and a healthy lifestyle.
  1.  Di Pierro F, Donato G, Fomia F, et al. Preliminary pediatric clinical evaluation of the oral probiotic Streptococcus salivarius K12 in preventing recurrent pharyngitis and/or tonsillitis caused by Streptococcus pyogenes and recurrent acute otitis media. Int J Gen Med. 2012; 5:991-7.
  2. Di Pierro F, Colombo M, Zanvit A, et al. Use of Streptococcus salivarius K12 in the prevention of streptococcal and viral pharyngotonsillitis in children. Drug, Healthc Pat Saf. 2014; 6:15-20.
  3. Gregori G, Righi O, Risso P, et al. Reduction of group A beta-hemolytic streptococcus pharyngo-tonsillar infections associated with use of the oral probiotic Streptococcus salivarius K12: a retrospective observational study. Ther Clin Risk Manag. 2016:12 87-92.
  4. Di Pierro F, Colombo M, Zambit A, Rottoli A. Positive clinical outcomes derived from using Streptococcus salivarius K12 to prevent streptococcal pharyngotonsillitis in children: a pilot investigation. Drug, Healthc Pat Saf. 2016; 8: 77-81.
  5. Di Pierro F, Colombo M, Giuliani MG, et al. Effect of administration of Streptococcus salivarius K12 on the occurrence of streptococcal pharyngo-tonsillitis, scarlet fever and acute otitis media in 3 years old children. Eur Rev Med Pharmacol Scien. 2016; 20: 4601-4606.
  6. Marini G, Sitzia M, Panatta ML, et al. Pilot study to explore the prophylactic efficacy of oral probiotic Streptococcus salivarius K12 in preventing recurrent pharyngo tonsillar episodes in pediatric patients. Int J Gen Med. 2019; 12: 213-217
  7. Di Pierro F, Adami T, Rapacioli G, et al. Clinical evaluation of the oral probiotic Bactoblis® in the prevention of recurrent pharyngitis and/or tonsillitis caused by Streptococcus pyogenes in adults. Expert Opin Biol Ther. 2013; 13(3):339-43

Streptococcus salivarius K12 and Oral Microbiota

Around 700 different kinds of microorganisms (including bacteria, fungi, viruses and protozoa) exist in the human mouth constituting the oral microbiota; it is the second-largest microbiota after the gut.

Oral cavity = First Line of Defence: Oral cavity harbours several beneficial bacterial species adepts at producing a diverse array of anti-competitor, antibacterial peptides molecules such as bacteriocins.

Streptococcus salivarius K12 produces the largest number of bacteriocins, most common being salivaricin A (SalA1-A5) and salivaricin B. These two salivaricins act as antagonists for certain pathogenic strains.

Studies also show that oral administration of the Streptococcus salivarius K12 can colonise the oropharynx, reduces IL-8 plasma concentrations and increases salivary interferon-γ.These activities may account for anti-inflammatory and anti-viral activity, in addition to the antibacterial action.

The four-step mechanism by which bacteriocins mediate their producers’ probiotic properties include:

  1. Pathogen invades mucosal membranes and produces active infection.
  2. It then supports colonisation of host by competitive inhibition of pathogenic microbiota.
  3. It may directly interact with a pathogenic target and inhibit it. Further
  4. it helps in immunomodulation by recruiting immune cells at the site to aid pathogen elimination.